LEESOL, a Korean healthcare startup specializing in electronic medicine for the prevention, diagnosis, and treatment of brain diseases, has secured KRW 4 billion (USD 2.96 million) in Series A funding from ViNe Ventures, Kolon Pharma, Korea Alternative Investment Corporation, New Paradigm Investment, and Find-US.

Founded in October 2017, LEESOL offers healthcare solutions for both mental illnesses such as sleep disorders and depression, as well as degenerative brain diseases like dementia. The company was co-founded by Dr. Seung-Woo Lee, who previously founded Medison, a pioneering medical device company, and Gu-Seong Kwon, a former patent attorney, who serves as co-CEO.

ViNe Ventures led the Series A round with an investment of KRW 1.5 billion (USD 1.11 million). Kolon Pharmaceuticals joined as a strategic investor focused on electronic medicine for depression, and New Paradigm Investments continued its backing following a pre-A investment.

LEESOL was recently selected by DeepTech TIPS, securing up to KRW 1.7 billion (USD 1.26 million) in R&D funding. Additionally, it was awarded a spot in the Ministry of Health and Welfare’s first health and medical technology development project, receiving an additional KRW 1.1 billion in R&D support.

LEESOL is developing a platform that diagnoses degenerative brain diseases (e.g., Alzheimer’s) and treats psychiatric disorders (e.g., sleep disorders, depression) using brain stimulation and brainwave tuning technology. In 2019, the company successfully developed “Sleepisol,” a device aimed at improving sleep disorders and preventing dementia through tACS-type cranial electrical stimulation (CES). The device has undergone multiple clinical trials at Seoul National University Bundang Hospital and has met the safety standards of the U.S. Food and Drug Administration (FDA). “Sleepisol,” which improves sleep disorders and prevents dementia by promoting the secretion of neurotransmitters like serotonin, melatonin, and GABA, is currently sold in Japan, the U.S., and Korea. Since its launch in May 2021, the “Sleepisol Series” has sold approximately 25,000 units, generating about KRW 2.3 billion (USD 1.70 million) in sales.

LEESOL CEO Gu-Seong Kwon expressed his gratitude, saying, “We are thankful to our investors for believing in LEESOL’s technology and development potential. We plan to continue expanding sales channels for wellness products alongside clinical trials for medical devices. Our mission is to innovate mental healthcare through brain science and create products that diagnose and treat a wide range of brain diseases, from sleep disorders to depression and dementia. Ultimately, we aim to become the world’s leading digital healthcare company, continually improving the quality of life for people around the globe.”